Home / Biosimilars

Biosimilars

News

Teriparatide biosimilar Terrosa launched in Europe posted 17/09/2019

Hungary-based Gedeon Richter (Richter) announced on 20 August 2019 that it had launched its teriparatide biosimilar Terrosa i...

Revance Therapeutics focus on its own Botox biosimilar as work with Mylan is stalled posted 17/09/2019

As Revance gives Mylan more time to decide whether to develop their joint Botox biosimilar, the firm is continuing to focus o...

Herzuma gains Japanese approval for three-week cycle method posted 17/09/2019

South Korean biotechnology company Celltrion announced at the end of August 2019 that Japan's Ministry of Health, Labour and...

Mylan launches adalimumab biosimilar Hulio in Spain posted 06/09/2019

US-based drugmaker Mylan announced on 9 July 2019 the launch of its adalimumab biosimilar, Hulio, in Spain; the company’s fir...

Heparin biosimilar to be marketed in Canada posted 05/09/2019

Canadian pharmaceuticals firm Valeo Pharma Inc has been given the rights to market a biosimilar version of low molecular weig...

 

Research

20920796_l More positive phase III results for rituximab biosimilar ABP 798 posted 17/09/2019

Biotech giant Amgen, and its partner Allergan, announced on 22 August 2019 positive data from a ‘top-line’ phase III study of...

Switching from reference to biosimilar infliximab in ankylosing spondylitis patients posted 17/09/2019

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the spine and the sacroiliac (SI) joints...

Positive results for Bio-Thera’s arthritis copy biologicals posted 06/09/2019

Immune specialists Bio-Thera Pharmaceuticals have begun a phase I trial for its Simponi copy biological and obtained positive...

Perceptions of biosimilars among US cancer patients posted 03/09/2019

Amid increasingly expensive cancer treatments, researchers in the US explored perceptions of generic drugs among a group of 7...

Turkey 2016 COVER V16E31DG Comparison of darbepoetin alfa and epoetin alfa for the treatment of renal anaemia posted 30/08/2019

Darbepoetin alfa (DA-α) manufactured by Hetero Biopharma (Hetero) is the first long-acting erythropoiesis-stimulating agent w...

 

General

Canadian IBD charity updates biosimilar position statement posted 17/09/2019

On 5 September 2019, Crohn’s and Colitis Canada announced that it had updated its position statement on the use of biosimilar...

Court rules Amgen’s patents on Enbrel are valid, Sandoz to appeal posted 06/09/2019

After the US District Court of New Jersey ruled in Amgen’s favour on the validity of its patents for arthritis treatment Enbr...

AB004665 Momenta drops Humira biosimilar development posted 30/08/2019

Momenta Pharmaceuticals Inc announced its financial results for the second quarter of 2019 on 2 August 2019. In this, they re...

Australia approves three biosimilars in first half of 2019 posted 23/08/2019

Australia’s regulatory agency, the Therapeutic Goods Agency (TGA) has up until the end of June 2019 approved three biosimilar...

Biosimilars applications under review by EMA – July 2019 posted 21/08/2019

The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A leg...